ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Head and neck squamous cell carcinoma (HNSCC) accounts for 3-5% of all tumor types and remains an unmet medical need with only two targeted therapies approved to date. ErbB3 (HER3), the kinase-impaired member of the EGFR/ErbB family, has been implicated as a disease driver in a number of solid tumor...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science (PLoS)
2017-01-01
|
| coleção: | PLoS ONE |
| Acesso em linha: | https://doi.org/10.1371/journal.pone.0181356 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|